Afaf Abed
YOU?
Author Swipe
View article: HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy
HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy Open
Introduction: Maximal heterozygosity on the human leukocyte antigen (HLA) loci has been found to be associated with improved survival and development of immune-related adverse events (irAEs) among NSCLC patients treated with immunotherapy.…
View article: Adjuvant immunotherapy in high-risk resectable melanoma: A real-world experience
Adjuvant immunotherapy in high-risk resectable melanoma: A real-world experience Open
Adjuvant immunotherapy with nivolumab or pembrolizumab represents the current standard of care for resected high-risk Stage III and IV malignant melanoma. However, data on its real-world outcomes and efficacy beyond clinical trials are lim…
View article: Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy Open
View article: 224P Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
224P Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy Open
View article: 1041P Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
1041P Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours Open
View article: Supplementary Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Supplementary Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy Open
Tables S1-S8 and Figures S1-S4
View article: Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy Open
Purpose:We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melanoma relative to type and line of treatment.Experimental Design:Plasma circulating tumor DNA (ctDNA) was quantif…
View article: Supplementary Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Supplementary Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy Open
Tables S1-S8 and Figures S1-S4
View article: Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Data from Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy Open
Purpose:We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melanoma relative to type and line of treatment.Experimental Design:Plasma circulating tumor DNA (ctDNA) was quantif…
View article: Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors
Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors Open
To investigate the association between skeletal muscle mass and adiposity measures with disease-free progression (DFS) and overall survival (OS) in patients with advanced lung cancer receiving immunotherapy, we retrospectively analysed 97 …
View article: 577 The variation of T-cell receptors (TCR) diversity and genomic human leukocyte antigen (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL-1 (≥50%) versus those with low or no PDL1 (<50%)
577 The variation of T-cell receptors (TCR) diversity and genomic human leukocyte antigen (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL-1 (≥50%) versus those with low or no PDL1 (<50%) Open
Background NSCLC patients with PDL1≥50% are more likely to respond to single agent anti-PD1 comparing to those who are expressing PDL1 in less than 50% of their cancer cells. This suggest that there might be biological differences among hi…
View article: A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab Open
Among patients treated with 1st-line immunotherapy, a higher HbA1c level (≥6.5%) indicated dismal OS, while history of DM, baseline blood glucose levels, and glucose changes during the treatment process were not significantly associated wi…
View article: Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients Open
View article: Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy Open
Homozygosity at one or more HLA-I loci may serve as biomarker to predict patients who are unlikely to experience severe irAEs among patients with NSCLC and treated with anti-PD1/PDL1, but less likely to derive clinical benefit. Patients wi…
View article: Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer Open
Overall, we identified a population of EpCAM-negative SCLC CTCs and showed that PD-L1 expression can be assessed on CTCs from SCLC patients. Comparison to tumour and treatment outcomes is needed to validate the potential of CTCs as an alte…
View article: HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced Melanoma
HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced Melanoma Open
Background:Predictive biomarkers of response to immune checkpoint inhibitors (ICI) are currently being evaluated in many studies. We evaluated whether germline Human Leukocyte Antigen (HLA) status can influence the response to immunotherap…
View article: 66 Prognostic and predictive value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy
66 Prognostic and predictive value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy Open
Background TCR repertoire plays a key role on the orchestration of the immune response. In particular, reduced pre-treatment Shannon diversity, increase clonality and increase convergence of TCRs have been suggested to reflect clonal expan…
View article: OA12.04 Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy
OA12.04 Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy Open
View article: Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression Open
Background The validity of circulating tumour DNA (ctDNA) as an indicator of disease progression compared to medical imaging in patients with metastatic melanoma requires detailed evaluation. Methods Here, we carried out a retrospective ct…
View article: FP12.07 Prognostic Value of HLA-I Homozygosity in Non-Small Cell Lung Cancer Patients Treated with Single Agent Immunotherapy
FP12.07 Prognostic Value of HLA-I Homozygosity in Non-Small Cell Lung Cancer Patients Treated with Single Agent Immunotherapy Open
View article: Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy Open
Background We aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II homozygosity on the survival benefit of patients with unresectable locally advanced, metastatic non-small lung cancer treated by single-agent programmed…
View article: 301MO Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy
301MO Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy Open
View article: Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis Open
Antibodies against programmed death-1 (PD-1), and its ligand, (PD-L1) have been approved recently for the treatment of small-cell lung cancer (SCLC). Although there are previous reports that addressed PD-L1 detection on tumour cells in SCL…
View article: Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study Open
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology. Our study evaluated the potential role of serum vascular …
View article: Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy Open